Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911898 · ClinicalTrials.gov registry record · Phase 1
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
A Phase 1 study of Metastatic Breast Cancer and Her2 Amplified Solid Tumors, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT00911898: Completed Phase 1 study of Metastatic Breast Cancer and Her2 Amplified Solid Tumors, sponsored by Merrimack Pharmaceuticals.
NCT00911898 is a Phase 1 study of Metastatic Breast Cancer and Her2 Amplified Solid Tumors that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 20 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00911898, a Phase 1 study of Metastatic Breast Cancer and Her2 Amplified Solid Tumors, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is an open-label Phase 1 trial of MM-111.
Primary Outcome
The Maximum Tolerated Dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. If a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded and an additional three patients (up to a total of six) are to be treated at the next lower dose level.
Conditions Studied
Interventions
- DRUG MM-111
Study Locations (4)
California
- University of Southern California Norris Comprehensive Cancer Center - Los Angeles
Indiana
- Indiana University (IUPUI) - Indianapolis
Pennsylvania
- Fox Chase Center - Philadelphia
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT00911898 record still lists
NCT00911898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MM-111 is the first listed.
NCT00911898 reports a single indexed study location in California, Indiana, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00911898 about?
NCT00911898 is a clinical study titled "A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers". This study is an open-label Phase 1 trial of MM-111.
What is the current status of trial NCT00911898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-06. Estimated completion is 2012-03.
What conditions does trial NCT00911898 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Her2 Amplified Solid Tumors.
What interventions are being tested in trial NCT00911898?
The interventions under investigation include: MM-111 (DRUG).
Who is sponsoring clinical trial NCT00911898?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00911898 being conducted?
This trial has 4 study locations across California, Indiana, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00911898's enrollment target sits among peer trials
20 119th of 139 higher than 18 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia